1 in 7 Russian Coronavirus Vaccine Volunteers Report Side Effects

Grant Boone
September 16, 2020

In the United States, regulators are more hesitant to resume the trial, with the government-funded National Institutes of Health having now launched an investigation of its own, Kaiser Health News reported Monday.

Speaking to Russian newspaper Izvestia, Murashko explained that more than 300 people have already received the Sputnik V vaccine as part of the three-phase trial, and 14 percent have complained about their health.

"Many have called to ask us some more detail about the risk of the vaccine, whether what happened with that vaccine had anything to do with the one we are studying, these types of questions", Borobia said.

The next most commonly reported symptoms were headache, muscle pain, chills and joint pain, respectively.

"The complications are described in the instructions and are predictable", he said.

Johnson & Johnson's Belgian Janssen unit began phase two trials of its COVID-19 vaccine on 190 people in Spain on Monday with those tests due to conclude on September 22.

Pfizer had said the US Food and Drug Administration (FDA) will consider issuing an emergency use authorization of a vaccine if it sees strong enough safety and efficacy data in a subset of the trial volunteers.

Northwestern to stay at 9th place in U.S
News college rankings, however, have faced widespread criticism and scrutiny from leaders in higher education. Boston College placed 35th in the 2021 survey of national universities released today by U.S.

"I can not say what the FDA will do", Bourla said.

'It is a must to release this data'.

AstraZeneca's COVID-19 vaccine trials were placed on hold worldwide on September 6 after a serious side effect was reported in one volunteer in Britain.

The British participant was rushed to the hospital after suffering a serious reaction that triggered spinal cord inflammation. AstraZeneca announced that the centres were recruiting up to 30,000 participants for the third phase trials in the United States. The name of the vaccine candidate is Covishield.

It trains the body to recognize the coronavirus, which will send out an immune response if a person becomes infected.

COVID-19 vaccines being developed in China might be available for use by the general public as early as November, according to a top scientist with the Chinese Center for Disease Control and Prevention (CDC).

"It may well be that one group has the right vaccine but the wrong delivery method, and only trials such as this will be able to tell us that", said Robin Shattock, who is leading the development of Imperial's vaccine.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER